Join the Asthma group to help and get support from people like you.
Asthma News (Page 8)
Related terms: Bronchial Asthma, Exercise-induced asthma, Wheezing
FDA Approves Nucala (mepolizumab) for Six to 11-Year-Old Children with Severe Eosinophilic Asthma
London UK - 12 September 2019 -- GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are ...
FDA Approves AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder for Asthma
JERUSALEM and PARSIPPANY, N.J., July 15, 2019 – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Di...
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options
London UK – 06 June 2019 – GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an a...
FDA Approves ProAir Digihaler (albuterol sulfate) as the First and Only Digital Inhaler with Built-In Sensors
JERUSALEM--(BUSINESS WIRE)--Dec 21, 2018--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (a...
FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma
RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) – Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (FDA) granted approval of its...
FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ – Sanofi (EURONEXT: SAN) (NYSE: SNY) The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy ...
GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
London, UK 21 May 2018 --GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled...
FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma
November 14, 2017 – AstraZeneca (NYSE:AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra...
FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
RIDGEFIELD, Conn., February 16, 2017 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat for the long-term,...
Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ArmonAir...
Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo...
Symbicort Approved for the Treatment of Asthma in Patients 6 to 12 Years of Age
26 January 2017 – AstraZeneca today announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of pediatric exclusivity for Symbicort (budesonide/formoterol)...
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA – July 7, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair...
Teva Announces FDA Approval of ProAir RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11
JERUSALEM--(BUSINESS WIRE)--Apr. 29, 2016-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick...
FDA Approves Cinqair (reslizumab) to Treat Severe Asthma
March 23, 2016 – The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18...
Further information
Related condition support groups
Asthma - Maintenance, Asthma - Acute
Related drug support groups
prednisone, methylprednisolone, albuterol, caffeine, triamcinolone, Dupixent, Medrol, Xolair, dexamethasone, view more... Trelegy Ellipta, fluticasone, omalizumab, montelukast, budesonide, dupilumab